**General Information**

**MAGICBULLET** consortium and scientific committee of the 5th International CeBiTec Research Conference:

Cesare Gennari (Università degli Studi di Milano, IT)  
Pirjo Laakkonen (University of Helsinki, FI)  
Gábor Mező (Eötvös Loránd University Budapest, HU)  
Ines Neundorf (University of Cologne, DE)  
Andreas Pahl (Heidelberg Pharma GmbH, Ladenburg, DE)  
Jan Anderl (Heidelberg Pharma GmbH, Ladenburg, DE)  
Umberto Piarulli (Università degli Studi dell’Insubria, IT)  
Norbert Sewald (Bielefeld University (Co-ordinator), DE)  
Christian Steinkühler (Exiris, Rome, IT)  
József Tóvári (National Institute of Oncology, Budapest, HU)

**Registration**  
For details regarding registration please visit [www.magicbullet.de](http://www.magicbullet.de)

**Location**  
Center for Interdisciplinary Research (ZiF)  
Methoden 1, 33615 Bielefeld  
[http://www.uni-bielefeld.de/ZiF](http://www.uni-bielefeld.de/ZiF)

**Accommodation**  
You are encouraged to book your accommodation in the Park Inn conference hotel, which provide special rates for conference participants.  
Please make your reservations mentioning group reference 24421 at  
**Park Inn by Radisson Bielefeld**  
Telephone: +49 521 9238-0  
Fax: +49 521 9238-250  
Email: info.bielefeld@eventhotels.com

**Further Information**  
For further information please contact [drugconjugates2015@uni-bielefeld.de](mailto:drugconjugates2015@uni-bielefeld.de)

---

**Arrival**

By car, you can take the A2 Dortmund - Hannover, exit at "Bielefeld-Zentrum", follow the street signs towards the center ("Zentrum"), and from there follow the signs to "Werther". From the "Wertherstraße", the ZiF is on the left side on the slope of the hill. The entrance is signposted.

Bielefeld can be reached from any major town by trains running on an hourly schedule (Eurocity train system: marked EC, IC, or ICE on the train schedule). From Bielefeld’s main station you can either take a taxi to the ZiF (approx. EUR 10,-) or take the underground tram line 4 (destination "Universität" or "Lohmannshof"). From the tram stop "Universität" you can reach the ZiF by walking up the hill behind the main building of the university (the way is signposted).
The Center for Biotechnology (CeBiTec) of Bielefeld University cordially invites you to attend the 5th International Bielefeld-CeBiTec Research Conference on "Drug Conjugates for Directed Therapy". The conference will be held at the Center for Interdisciplinary Research (ZiF) of Bielefeld University from September 20th to 23rd, 2015.

CeBiTec Research Conferences are annual events with thematic focus on a challenging topic in the life sciences. The 2015 conference Drug Conjugates for Directed Therapy is being organized by the Marie Skłodowska-Curie European Training Network MAGICBULLET (www.magicbullet.de), which is currently being funded by the EU in the Horizon 2020 Framework Programme for Research and Innovation.

The scope of the CeBiTec Research Conference will include:

- Antibody-Drug Conjugates
- Peptide-Drug Conjugates
- Targets and Specificity
- New Drugs
- Linker Technologies
- Applications
- Process Development

The meeting will feature plenary lectures, poster presentations and short presentations.

We look very much forward to welcome you in Bielefeld!

The conference committee

Confirmed plenary speakers

Jan Anderl  Heidelberg Pharma, DE
Antibody-Drug Conjugates targeting RNA polymerase II

James Baker  University College London, UK
The Next Generation Maleimide platform for the construction of homogeneous protein conjugates

Annette Beck-Sickinger  Leipzig University, DE
Targeted cancer diagnosis and therapy with peptide conjugates

Ravi J. Chari  ImmunoGen, Waltham, US
Antibody-Drug Conjugates: Pathway from a concept to the clinic

Donald M. Engelman  Yale University, US
pHLIP® targeting and delivery of PNA in vivo to silence microRNA in acidic tumor cells

Cesare Gennari  Università degli Studi di Milano, IT
Tumor targeting via integrin ligands: Synthesis and biological evaluation of RGD peptidomimetic-Paclitaxel conjugates

Ulf Grawunder  NBE Therapeutics, CH
SMAC-Technology – generation of site-specifically conjugated ADCs by highly efficient enzymatic conjugation

Nicolas Joubert  Université de Tours, FR
A new chemical platform for the modular construction of homogeneous Antibody-Drug Conjugates

Horst Kessler  TU München, DE
Selective addressing integrin subtypes for drug research, molecular imaging and biophysical studies

Felix Kratz  CyRx Corporation, DE
Albumin-based drug delivery systems in oncology: From bench to bedside

Pirjo Laakkonen  Biomedicum Helsinki, FI
Peptide-based tumor targeting

Maxime Lampilas  Sanofi, Vitry sur Seine, FR
Process development of SPDB/DM4 conjugates

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 642004.